Revolutionary Breakthrough in Liver Disease Diagnosis: Modena Polyclinic Tests Latest Fibroscan Prototype
The Modena Polyclinic has made history by becoming the first healthcare facility in the world to test the latest prototype of Fibroscan, a groundbreaking tool that enables non-invasive diagnosis of chronic liver diseases. This innovative technology has the potential to transform the way liver diseases are diagnosed and treated, and the Modena Polyclinic is at the forefront of this medical breakthrough.
Collaboration with Echosens and Professor Filippo Schepis
Echosens, the company behind Fibroscan, has partnered with the research group led by Professor Filippo Schepis, head of the Complex Liver Diseases structure and the Hepatic Hemodynamics Laboratory of the Polyclinic. This collaboration has resulted in the testing of the latest generation machine, with the goal of setting an international standard in liver diagnostics. The agreement was presented in the presence of Laurent Sandrin, inventor of Fibroscan and CEO of Echosens, highlighting the significance of this partnership.
The Hepatic Hemodynamics Laboratory, founded in 2009, is recognized as one of the most advanced in Europe for the diagnosis and treatment of portal hypertension associated with liver cirrhosis and rare vascular diseases of the liver. With around 300 procedures performed annually, the laboratory has established itself as a leader in the field. The path to this experimentation began three years ago, and the Modena laboratory is one of the few in the world capable of comparing the measurements of this special prototype with invasive reference data.
Fibroscan: A Game-Changer in Liver Disease Diagnosis
Fibroscan has revolutionized the way liver diseases are diagnosed, allowing for non-invasive measurement of liver stiffness, an indirect indicator of fibrosis. This technology eliminates the need for biopsies, which require tissue samples and can be painful and risky for patients. By simply placing a probe on the patient’s abdomen, healthcare professionals can quickly and accurately assess liver health. Echosens has made the only prototype example in the world available, along with the latest commercial model of the Fibroscan 630 Expert, worth 200 thousand euros.
The implications of this technology are significant, and the data collected during this testing phase will set an international standard in liver diagnostics. As a result, patients with liver diseases will benefit from more accurate diagnoses and targeted treatments, improving their overall quality of life. For more information on this groundbreaking technology and the Modena Polyclinic’s role in its development, visit Here